On your MARCKS, get set, deliver: Engineering extracellular vesicles

Extracellular vesicles (EVs) serve as drug delivery platforms that are, in some cases, superior to synthetic nanoparticles.1 EVs comprise lipid bilayer-enclosed cytoplasmic content and naturally include membrane-associated proteins, several of which have been used for engineering and cargo loading. Since some of these proteins are limited by meager cellular expression and low EV density, Dooley et al.2 (in this issue of Molecular Therapy) at Codiak BioSciences rigorously sought membrane-associated proteins that are highly expressed and enriched in EVs and thus well suited for novel applications in EV engineering.